Study of a new drug for advanced DLL3-positive solid tumors
Part of Cancer, Infections, Lungs & breathing clinical trials.
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of the listed cancer types that has progressed after at least one prior treatment.
- For some cancer types, you must have a measurable tumor that shows uptake of a special imaging agent.
- You must not have certain medical conditions like severe kidney problems, uncontrolled urinary issues, or active brain metastases.
- You must not have had certain prior treatments, depending on your cancer type.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
This trial is testing a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare type of cancer called LCNEC or EP-NEC that has spread. The goal is to see if this combination can help shrink or control the cancer and improve outcomes.
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.